阿斯匹林治疗急性缺血性脑卒中临床疗效随机双盲对照研究

Randomized Double Blind Placebo-controlled Clinical Therapeutic Trial of Aspirin in Patients With Acute Ischemic Stroke

目的 探讨阿斯匹林抗血小板治疗急性缺血性脑卒中 ,对降低死亡率 ,改善致残率的临床疗效。 方法 采取随机、双盲、安慰剂对照 ,对发病 4 8h内的急性缺血性脑卒中患者 ,均经头颅 CT检查排除出血性脑卒中。入选患者在常规治疗的基础上 ,口服阿斯匹林 ,每天 1 6 0 mg或安慰剂 4周。 结果 服阿斯匹林的患者 (阿斯匹林组 )和服安慰剂的患者 (安慰剂组 )相比较 ,两组对降低死亡率 ,减轻致残率的结果差异无统计学意义 ( P >0 .0 5 )。 结论 在常规治疗急性缺血性脑卒中的基础上 ,加服阿斯匹林1 6 0 mg对降低病死率和出院时的致残率效果不明显。

Objective To obtain a reliable assessment of aspirin effects on mortality and on disability in surviors of acute ischmic stroke. Methods This study was a randomised double blind placebo controlled trial of the effects in patients with aspirin treatment 160mg perday and routine treatment started with in 48h of the onset of suspected acute ischemic stroke and continued in hospital for up to 4weeks. Results There was no significant reduction in mortality and disahility between aspirin group and placebo group. Conclusion This study suggested that there was no significant effect on mortality and disability of patients with aspirin 160mg per day and routine treatment.